Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Non-Current Deffered Revenue (2019 - 2021)

Harmony Biosciences Holdings' Non-Current Deffered Revenue history spans 3 years, with the latest figure at $192000.0 for Q1 2021.

  • For Q1 2021, Non-Current Deffered Revenue changed N/A year-over-year to $192000.0; the TTM value through Mar 2021 reached $192000.0, changed N/A, while the annual FY2020 figure was $212000.0, 26.13% down from the prior year.
  • Non-Current Deffered Revenue for Q1 2021 was $192000.0 at Harmony Biosciences Holdings, down from $212000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $305000.0 in Q3 2020 and bottomed at $192000.0 in Q1 2021.
  • The 3-year median for Non-Current Deffered Revenue is $249500.0 (2019), against an average of $249000.0.
  • The largest YoY upside for Non-Current Deffered Revenue was 26.13% in 2020 against a maximum downside of 26.13% in 2020.
  • A 3-year view of Non-Current Deffered Revenue shows it stood at $287000.0 in 2019, then decreased by 26.13% to $212000.0 in 2020, then decreased by 9.43% to $192000.0 in 2021.
  • Per Business Quant, the three most recent readings for HRMY's Non-Current Deffered Revenue are $192000.0 (Q1 2021), $212000.0 (Q4 2020), and $305000.0 (Q3 2020).